Company profile

Mitchell H. Gold
Incorporated in
Fiscal year end
Former names
N30 Pharmaceuticals, Inc., Nivalis Therapeutics, Inc.

ALPN stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


14 Nov 19
22 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 289K 567K 0 0
Net income -11.48M -11.86M -12.38M -11.14M
Diluted EPS -0.62 -0.64 -0.7 -0.8
Net profit margin -3971% -2091%
Operating income -11.71M -12.15M -12.7M -11.45M
Net change in cash -2.72M 1.7M 1.29M -1.99M
Cash on hand 880K 3.6M 1.9M 614K
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 705K 1.73M 0 0
Net income -36.49M -7.78M -1.23M -369K
Diluted EPS -2.63 -1.2 -2.18 -0.74
Net profit margin -5175% -450%
Operating income -37.83M -14.97M -1.19M -371K
Net change in cash -1.69M -9.5M -13.19M -2.82M
Cash on hand 614K 2.3M 11.8M 24.99M

Financial data from company earnings reports

13F holders
Current Prev Q Change
Total holders 0 0 NaN%
Opened positions 0 0 NaN%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • We will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.
  • Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.
  • The market may not be receptive to our therapeutic products based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic products.
  • Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.
  • Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier pre-clinical and clinical trials may not be predictive of future clinical trial results.
  • To date, our revenue has been primarily derived from our collaboration agreements, and our success is dependent, in part, on our collaborators’ efforts to develop our therapeutic candidates.
  • If third parties on which we depend to conduct our clinical or preclinical studies, or any future clinical trials, do not perform as expected, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed, which may result in materially adverse effects on our business, financial condition, results of operations, and prospects.
  • Because we rely on third party manufacturing and supply partners, our supply of clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality, and our dependence on these third parties may impair the advancement of our research and development programs.
  • We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expenses, and present significant distractions to our management.
  • We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.
  • Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.
  • As our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations.
  • If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we may be unable to successfully commercialize any such future products.
  • If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.
  • Imposed price controls may adversely affect our future profitability.
  • Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could harm our business, financial condition, results of operations, or prospects.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we conduct business.
  • Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology.
  • Our information technology systems could face serious disruptions adversely affecting our business.
  • Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences.
  • The investment of our cash, cash equivalents, and fixed income in marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.
  • Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies.
  • Our net operating loss carryforwards and certain other tax attributes are likely subject to limitations.
  • Our business may be affected by litigation and government investigations.
  • We believe our development programs and platform have a particular mechanism of action, but this mechanism of action has not been proven conclusively.
  • Any inability to present our data in scientific journals or at scientific conferences could adversely impact our business and stock price.
  • Our business may be affected by adverse scientific publications or editorial or discussant opinions.
  • If we are not able to obtain and enforce patent protection for our technology, including therapeutic candidates, therapeutic products, and platform technology, development of our therapeutic candidates and platform, and commercialization of our therapeutic products may be materially and adversely affected.
  • We may license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be materially and adversely affected.
  • We may be unable to protect our patent intellectual property rights throughout the world.
  • We or our licensors, collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development of our therapeutic candidates and commercialization of our therapeutic products, or put our patents and other proprietary rights at risk.
  • If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights necessary for developing and protecting our technology, including our platform technology, therapeutic candidates, and therapeutic products, or we could lose certain rights to grant sublicenses, either of which could have a material adverse effect on our results of operations and business prospects.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may be in the future subject to claims we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees’ or consultants’ former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages, may be prohibited from using some of our research and development and may lose valuable intellectual property rights or personnel.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be materially and adversely affected.
  • Third parties may independently develop similar or superior technology.
  • Breaches of our internal computer systems, or those of our contractors, vendors, or consultants, may place our patents or proprietary rights at risk.
  • We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our therapeutic candidates.
  • If we fail to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for certain of our products, our competitors may sell products to treat the same conditions and our revenue may be reduced.
  • If we or our existing or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or such other parties could be subject to enforcement actions, which could adversely affect our ability to develop, market, and sell our therapeutics and may harm our reputation.
  • Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our therapeutic candidates.
  • Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, thereby harming our business.
  • The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition.
  • Our ability to obtain services, reimbursement, or funding from the federal government may be impacted by possible reductions in federal spending.
  • If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic product, our ability to market and derive revenue from the therapeutic products could be compromised.
  • Our therapeutic candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
  • Significant developments stemming from the United Kingdom’s recent referendum on membership in the European Union could have a material adverse effect on us.
  • Our stock price may be volatile, and an active, liquid, and orderly trading market may not develop for our common stock. As a result, stockholders may not be able to resell shares at or above their purchase price.
  • Our officers and directors, and their respective affiliates, have a controlling influence over our business affairs and may make business decisions with which stockholders disagree and which may adversely affect the value of their investment.
  • Future sales, or the perception of future sales, of a substantial amount of our common stock could depress the trading price of our common stock.
  • We will have broad discretion over the use of the proceeds to us from our financing activities and may apply the proceeds to uses that do not improve our operating results or the value of your securities.
  • The JOBS Act allows us to postpone the date by which we must comply with certain laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC. We cannot be certain if this reduced disclosure will make our common stock less attractive to investors.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • We will continue to incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
  • Anti-takeover provisions in our charter documents and under Delaware or Washington law could discourage, delay or prevent a change in control of our company, limit attempts by our stockholders to replace or remove our current management and may affect the trading price of our common stock.
  • Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of available cash.
  • Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
  • We do not expect to pay any dividends on our common stock for the foreseeable future.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • Nasdaq may delist our common stock from its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
Management Discussion
  • Revenue for the three months ended September 30, 2019 consists of $0.3 million related to the Adaptimmune Collaboration Agreement. We had no revenue during the three months ended September 30, 2018.
  • The $1.0 million decrease in research and development expenses was primarily attributable to a decrease of $3.8 million in contract manufacturing and process development of our product candidates and a decrease of $0.8 million in direct research activities. These decreases were partially offset by an increase of $2.2 million in clinical trial activity, an increase of $0.7 million in personnel-related expenses as a result of growth in headcount to support ongoing discovery and development programs, an increase of $0.2 million in stock-based compensation, and an increase of $0.5 million in allocated overhead and facilities.
  • The $0.6 million increase in general and administrative expenses was primarily attributable to a $0.4 million increase in professional and legal services, an increase of $0.1 million in personnel-related expenses related to an increase in administrative headcount and an increase of $0.1 million in facility costs to support the growth and expansion of our business.
Content analysis ?
H.S. junior Avg
New words: acute, comparison, cytokine, deadline, duration, escalation, exhibited, extinguishment, fight, floor, graft, GVHD, host, humoral, immunogenicity, installment, intravenously, mortality, PD, pharmacodynamic, pharmacokinetic, PK, potent, prepay, prepayment, PSMA, psoriatic, refinancing, refractory, resistant, rheumatoid, Scheduled, Sjogren, steroid, storm, strongly, subcutaneously, SVB, syndrome, worsened
Removed: acceleration, amortize, buy, consecutive, drawdown, fourth, pledged, point